Currently, there are 74.76M common shares owned by the public and among those 69.80M shares have been available to trade.
The company’s stock has a 5-day price change of -6.70% and -11.94% over the past three months. ALGN shares are trading -22.08% year to date (YTD), with the 12-month market performance down to -21.47% lower. It has a 12-month low price of $196.09 and touched a high of $335.40 over the same period. ALGN has an average intraday trading volume of 800.49K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.29%, -3.98%, and -15.03% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Align Technology, Inc (NASDAQ: ALGN) shares accounts for 89.24% of the company’s 74.76M shares outstanding.
It has a market capitalization of $15.94B and a beta (3y monthly) value of 1.67. The stock’s trailing 12-month PE ratio is 36.40, while the earnings-per-share (ttm) stands at $5.87. The company has a PEG of 3.58 and a Quick Ratio of 1.14 with the debt-to-equity ratio at 0.03. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.90% over the week and 3.44% over the month.
Earnings per share for the fiscal year are expected to increase by 8.53%, and 9.87% over the next financial year. EPS should grow at an annualized rate of 10.17% over the next five years, compared to 3.39% over the past 5-year period.
Looking at the support for the ALGN, a number of firms have released research notes about the stock. Mizuho stated their Outperform rating for the stock in a research note on December 04, 2024, with the firm’s price target at $295. Leerink Partners was of a view on February 26, 2024 that the stock is Market Perform, while Goldman gave the stock Sell rating on December 11, 2023, issuing a price target of $197. UBS on their part issued Neutral rating on October 27, 2023.
